MX381844B - Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos - Google Patents

Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos

Info

Publication number
MX381844B
MX381844B MX2017011189A MX2017011189A MX381844B MX 381844 B MX381844 B MX 381844B MX 2017011189 A MX2017011189 A MX 2017011189A MX 2017011189 A MX2017011189 A MX 2017011189A MX 381844 B MX381844 B MX 381844B
Authority
MX
Mexico
Prior art keywords
dsbc
dsba
methods
ultrapurified
preparing
Prior art date
Application number
MX2017011189A
Other languages
English (en)
Other versions
MX2017011189A (es
Inventor
Amy Lim
Chris B Fong
Liliana T Yee
Marc Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2017011189A publication Critical patent/MX2017011189A/es
Publication of MX381844B publication Critical patent/MX381844B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
    • C12Y108/04002—Protein-disulfide reductase (glutathione) (1.8.4.2), i.e. BdbC or BdbD
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90212—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Cephalosporin Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)

Abstract

La presente invención se refiere a un método para purificar un polipéptido de disulfuro oxidorreductasaa A (DsbA) de un lisado celular que comprende el polipéptido de DsbA, el método comprende a) agregar polietilenimina (PEI) a una concentración final de alrededor de 0.01% a 1.0 %, preferiblemente 0.1%, a un lisado celular que comprende el polipéptido DsbA, b) clarificar el lisado celular mediante centrifugación, c) aplicar el lisado celular clarificado que comprende el polipéptido de DsbA a un material de cromatografía de intercambio, aniónico, d) eluir el polpéptido de DsbA del material de cromatografía de intercambio aniónico para generar un eluido de intercambio aniónico que comprende el polipéptido de DsbA, e) aplicar el eluidoo de intercambio aniónico que comprende el polipéptido de DsbA a un material de cromatografía de intercambio catiónico, f) eluir el polipéptido de DsbA del material de cromatografía de intercambio catiónico para generar un eluido de intercambio catiónico que comprende el polipéptido de DsbA purificado, en donde el DsbA comprende al menos 95% de polipéptido DsbA monomérico.
MX2017011189A 2015-03-06 2016-03-04 Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos MX381844B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129701P 2015-03-06 2015-03-06
PCT/US2016/021059 WO2016144824A1 (en) 2015-03-06 2016-03-04 Ultrapurified dsba and dsbc and methods of making and using the same

Publications (2)

Publication Number Publication Date
MX2017011189A MX2017011189A (es) 2018-01-23
MX381844B true MX381844B (es) 2025-03-13

Family

ID=55637452

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000153A MX387454B (es) 2015-03-06 2016-03-04 DsbA Y DsbC ULTRAPURIFICADO Y MÉTODOS PARA ELABORARLOS Y UTILIZARLOS.
MX2017011189A MX381844B (es) 2015-03-06 2016-03-04 Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021000153A MX387454B (es) 2015-03-06 2016-03-04 DsbA Y DsbC ULTRAPURIFICADO Y MÉTODOS PARA ELABORARLOS Y UTILIZARLOS.

Country Status (17)

Country Link
US (2) US10073098B2 (es)
EP (2) EP3636749B1 (es)
JP (2) JP6865689B2 (es)
KR (1) KR20170122216A (es)
CN (1) CN107531749A (es)
AR (1) AR103852A1 (es)
AU (1) AU2016230018A1 (es)
CA (1) CA2978256A1 (es)
ES (1) ES2761726T3 (es)
HK (1) HK1247936A1 (es)
HR (1) HRP20192217T1 (es)
IL (1) IL254166A0 (es)
MX (2) MX387454B (es)
PL (1) PL3265557T3 (es)
SG (2) SG11201707186YA (es)
SI (1) SI3265557T1 (es)
WO (1) WO2016144824A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
ES2761726T3 (es) 2015-03-06 2020-05-20 Hoffmann La Roche DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
TWI870412B (zh) * 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法
MX2022011780A (es) 2020-04-09 2022-11-10 Cytomx Therapeutics Inc Composiciones que contienen anticuerpos activables.
US12540929B2 (en) * 2021-12-17 2026-02-03 Dionex Corporation Desalting system for chromatography
CN115028691B (zh) * 2022-06-29 2024-09-10 青岛硕景生物科技有限公司 一种检测试纸用的独立质控系统、杂交瘤细胞株、质控线用包被单克隆抗体及其应用
CN119874933A (zh) * 2024-11-20 2025-04-25 金宇保灵生物药品有限公司 一种基于大肠杆菌的纳米抗体融合表达体系及其制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (es) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
GB9325718D0 (en) * 1993-12-16 1994-02-16 Ars Holding 89 Nv Sensor device for sandwich assay
US5639635A (en) * 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2000083670A (ja) * 1998-09-09 2000-03-28 Hsp Kenkyusho:Kk ＤｓｂＡ／ＤｓｂＢ／ＤｓｂＣ／ＤｓｂＤ発現プラスミド
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2364568A1 (en) * 1999-03-17 2000-09-21 Adrian Woolfson Method for refolding molecules of polypeptides containing ig domains
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
MXPA03005273A (es) 2000-12-14 2003-09-25 Genentech Inc Anticuerpos producidos procarioticamente y sus usos.
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
CN100475965C (zh) 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
MX2009007632A (es) * 2007-01-22 2009-07-24 Genentech Inc Precipitacion de polielectrolito y purificacion de proteinas.
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
CN105274170A (zh) * 2009-11-05 2016-01-27 弗·哈夫曼-拉罗切有限公司 分泌异源多肽的方法和组合物
AU2010201410B2 (en) * 2010-03-30 2015-04-30 Pelican Technology Holdings, Inc. High level expression of recombinant CRM197
GB201012519D0 (en) 2010-07-26 2010-09-08 Ucl Business Plc Method and system for anomaly detection in data sets
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
MX2014005330A (es) * 2011-11-02 2014-09-08 Genentech Inc Cromatografia de sobrecarga y elucion.
SG10202108497TA (en) * 2013-04-19 2021-09-29 Sutro Biopharma Inc Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
KR102332302B1 (ko) * 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
ES2761726T3 (es) 2015-03-06 2020-05-20 Hoffmann La Roche DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas

Also Published As

Publication number Publication date
MX2017011189A (es) 2018-01-23
US20160370369A1 (en) 2016-12-22
KR20170122216A (ko) 2017-11-03
CA2978256A1 (en) 2016-09-15
AR103852A1 (es) 2017-06-07
CN107531749A (zh) 2018-01-02
HRP20192217T1 (hr) 2020-02-21
JP7191132B2 (ja) 2022-12-16
IL254166A0 (en) 2017-10-31
EP3265557B1 (en) 2019-10-16
AU2016230018A1 (en) 2017-09-21
US10073098B2 (en) 2018-09-11
SI3265557T1 (sl) 2020-02-28
JP2018516229A (ja) 2018-06-21
MX387454B (es) 2025-03-18
EP3636749B1 (en) 2022-04-27
JP2021078502A (ja) 2021-05-27
EP3636749A1 (en) 2020-04-15
JP6865689B2 (ja) 2021-04-28
MX2021000153A (es) 2021-10-28
US20190056399A1 (en) 2019-02-21
WO2016144824A1 (en) 2016-09-15
SG10202005917SA (en) 2020-07-29
US10690671B2 (en) 2020-06-23
SG11201707186YA (en) 2017-10-30
HK1247936A1 (zh) 2018-10-05
ES2761726T3 (es) 2020-05-20
EP3265557A1 (en) 2018-01-10
PL3265557T3 (pl) 2020-03-31

Similar Documents

Publication Publication Date Title
MX2021000153A (es) Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos.
AR105602A1 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
BR112019012343A2 (pt) anticorpos il-11ra
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2016009965A (es) Produccion de alta titulacion de vectores virales adenoasociados.
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA202092435A2 (ru) Моноклональные антитела против bcma
TWD170353S (zh) 項鍊
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
WO2016033437A3 (en) Polyethers, polyamines, polythioethers, and methods for making same
ZA201703510B (en) Antibodies, uses & methods
BR112016017584A2 (pt) Composições de nanotribologia e métodos relacionados incluindo nanofolhas moleculares
MX384727B (es) Procesos para preparar oligómeros
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2021007143A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.
MX384182B (es) Microorganismo recombinante para la produccion mejorada de quimicos finos.
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
EA201791491A1 (ru) Способы выделения тромбоцитов
CL2017001633A1 (es) Método de manufactura de proteína.
MX2020012065A (es) Compuestos de ciclopentano.